Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

ATRA

Atara Biotherapeutics Inc

Apr 18 • 04:00PM ET

0.6917

Dollar change -0.0232
Percentage change -3.25	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN SCHA VTWO VHT IWC FESM IWO

Index	RUT	P/E	-	EPS (ttm)	-2.61	Insider Own	7.74%	Shs Outstand	119.36M	Perf Week	-2.96%
Market Cap	82.56M	Forward P/E	-	EPS next Y	-0.40	Insider Trans	8.23%	Shs Float	110.12M	Perf Month	1.30%
Income	-276.13M	PEG	-	EPS next Q	-0.26	Inst Own	60.76%	Short Float	10.20%	Perf Quarter	-5.25%
Sales	8.57M	P/S	9.63	EPS this Y	79.08%	Inst Trans	-0.33%	Short Ratio	4.13	Perf Half Y	-55.94%
Book/sh	-0.93	P/B	-	EPS next Y	26.01%	ROA	-101.91%	Short Interest	11.23M	Perf Year	-76.63%
Cash/sh	0.43	P/C	1.59	EPS next 5Y	-	ROE	-2014.86%	52W Range	0.20 - 3.08	Perf YTD	34.89%
Dividend Est.	2.00 (289.14%)	P/FCF	-	EPS past 5Y	13.12%	ROI	-	52W High	-77.54%	Beta	0.69
Dividend TTM	-	Quick Ratio	0.65	Sales past 5Y	25.21%	Gross Margin	-99.79%	52W Low	248.29%	ATR (14)	0.07
Dividend Ex-Date	-	Current Ratio	0.72	EPS Y/Y TTM	-16.73%	Oper. Margin	-3140.98%	RSI (14)	46.61	Volatility	8.16% 9.54%
Employees	225	Debt/Eq	-	Sales Y/Y TTM	-86.51%	Profit Margin	-3220.88%	Recom	2.60	Target Price	4.20
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	22.66%	Payout	-	Rel Volume	0.30	Prev Close	0.71
Sales Surprise	65.96%	EPS Surprise	-25.84%	Sales Q/Q	1823.98%	Earnings	Mar 28 BMO	Avg Volume	2.72M	Price	0.69
SMA20	-2.96%	SMA50	-6.85%	SMA200	-38.16%	Trades		Volume	830,302	Change	-3.25%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-09-23	Downgrade	Mizuho	Buy → Neutral	$31 → $1
Nov-09-23	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-09-23	Downgrade	Evercore ISI	Outperform → In-line
Jul-20-22	Downgrade	Citigroup	Neutral → Sell	$8 → $3
Jul-13-22	Downgrade	Stifel	Buy → Hold	$16 → $5
Jul-13-22	Downgrade	JP Morgan	Overweight → Neutral	$10
May-10-22	Downgrade	Citigroup	Buy → Neutral	$15 → $8
May-13-21	Upgrade	JP Morgan	Neutral → Overweight	$23 → $29
Dec-09-20	Downgrade	Citigroup	Buy → Neutral	$20 → $27
Dec-08-20	Reiterated	H.C. Wainwright	Buy	$28 → $31
Nov-10-20	Reiterated	H.C. Wainwright	Buy	$26 → $28
Jun-30-20	Initiated	Evercore ISI	Outperform
Jun-15-20	Initiated	H.C. Wainwright	Buy	$25
Apr-23-20	Upgrade	Citigroup	Neutral → Buy	$14
Nov-08-19	Downgrade	JP Morgan	Overweight → Neutral	$43 → $22
Sep-27-19	Downgrade	Goldman	Neutral → Sell	$14 → $9
Sep-16-19	Downgrade	Jefferies	Buy → Hold	$32 → $15
Jun-04-19	Upgrade	Citigroup	Sell → Neutral	$23 → $24
May-30-19	Initiated	ROTH Capital	Buy
May-23-19	Initiated	Stifel	Buy

Show Previous Ratings

Apr-05-24 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-28-24 01:53PM	ATRA Stock Earnings: Atara Biotherapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
09:40AM	Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:40AM	Atara Biotherapeutics: Q4 Earnings Snapshot (Associated Press Finance)
08:30AM	Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress (Business Wire)
09:05AM	Loading…
Feb-29-24 09:05AM	Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy (Business Wire)
Feb-28-24 04:30PM	Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference (Business Wire)
Feb-14-24 09:00AM	Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis (Business Wire)
Jan-31-24 06:30PM	Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel Data in The Lancet Oncology (Business Wire)
Jan-11-24 01:26AM	Seth Klarman's Firm Exits Atara Biotherapeutics Inc Holding (GuruFocus.com) +5.31%
01:26AM	Seth Klarman's Exit from Atara Biotherapeutics Inc (GuruFocus.com)
Jan-08-24 09:00AM	Atara Biotherapeutics Announces $15 Million Registered Direct Offering (Business Wire) +25.28%
08:00AM	Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-04-24 04:01PM	Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-20-23 04:01PM	Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel Partnership with Pierre Fabre Laboratories (Business Wire)
12:00PM	Loading…
Dec-11-23 12:00PM	Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting (Business Wire)
Dec-01-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-29-23 06:05PM	Atara Biotherapeutics To Present Positive New Tab-cel Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023 (Business Wire) +13.36%
Nov-24-23 12:29PM	Atara Biotherapeutics (ATRA) Slumps 57% in a Month: Here's Why (Zacks) +13.93%
Nov-22-23 04:01PM	Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference (Business Wire) +13.22%
09:14AM	Billionaire Seth Klarmans Biotech Stock Picks (Insider Monkey)
Nov-10-23 04:01PM	Atara Biotherapeutics To Participate at the Stifel Healthcare Conference (Business Wire)
Nov-09-23 08:23AM	Why Is Atara Biotherapeutics (ATRA) Stock Down 50% Today? (InvestorPlace) -80.17%
06:40AM	Ataras cell therapy approach to MS falls short in study (BioPharma Dive)
Nov-08-23 05:35PM	Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis (Business Wire) -9.02%
Nov-05-23 12:50PM	Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 05:42AM	Atara Biotherapeutics Inc (ATRA) Announces Q3 2023 Financial Results and Expanded Global Partnership (GuruFocus.com) -5.56%
02:25AM	Q3 2023 Atara Biotherapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-01-23 08:35AM	Atara Biotherapeutics: Q3 Earnings Snapshot (Associated Press Finance)
08:30AM	Atara Biotherapeutics Announces Expanded Global Tab-cel Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results (Business Wire)
04:01PM	Loading…
Oct-06-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-21-23 09:19AM	Atara (ATRA) Up 11% on Regulatory Update From Blood Cancer Study (Zacks)
Sep-19-23 04:01PM	Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on Comparability (Business Wire)
Sep-01-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.16%
Aug-31-23 04:01PM	Atara Biotherapeutics to Participate in Cell Therapies in Autoimmune Panel Discussion at the Citi 18th Annual BioPharma Conference (Business Wire)
Aug-13-23 10:44AM	10 Most Promising Penny Stocks According to Analysts (Insider Monkey)
Aug-08-23 05:30PM	Atara Biotherapeutics (ATRA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:18PM	Atara Biotherapeutics: Q2 Earnings Snapshot (AP Finance)
04:01PM	Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress (Business Wire)
Aug-04-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-01-23 04:01PM	Atara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023 (Business Wire)
Jul-31-23 04:01PM	Atara Biotherapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference (Business Wire) +7.28%
Jul-29-23 11:07AM	10 Stocks That Will Go Up 1000 Percent (Insider Monkey)
Jul-17-23 07:29AM	3 Doomed Biotech Stocks Destined for Disaster (InvestorPlace) +6.56%
Jul-07-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +11.45%
Jun-16-23 06:05AM	Time To Worry? Analysts Just Downgraded Their Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Outlook (Simply Wall St.) -6.07%
Jun-07-23 04:01PM	Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference (Business Wire)
Jun-05-23 09:00AM	Atara Biotherapeutics Presents Updated Tab-cel® Clinical Effectiveness Data at ASCO 2023 (Business Wire)
Jun-02-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-18-23 07:09AM	Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Analysts Are More Bearish Than They Used To Be (Simply Wall St.)
May-08-23 05:15PM	Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:12PM	Atara Biotherapeutics: Q1 Earnings Snapshot (AP Finance)
04:01PM	Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress (Business Wire)
May-07-23 08:59AM	The Market Doesn't Like What It Sees From Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Revenues Yet (Simply Wall St.)
May-05-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.82%
May-01-23 04:01PM	Atara Biotherapeutics to Announce First Quarter 2023 Financial Results on Monday, May 8, 2023 (Business Wire)
Apr-16-23 12:08PM	3 Stocks to Buy That Could Be the Next Biotech Breakthrough (InvestorPlace)
Mar-31-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-24-23 09:35AM	Atara Biotherapeutics (ATRA) Loses -33.02% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Mar-03-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:40AM	Are Medical Stocks Lagging Apexigen, Inc. (APGN) This Year? (Zacks)
Mar-01-23 04:01PM	Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 43rd Annual Health Care Conference (Business Wire)
Feb-21-23 04:01PM	Atara Biotherapeutics to Participate in the H.C. Wainwright Cell Therapy Virtual Conference (Business Wire) -9.96%
Feb-15-23 06:58AM	The past five years for Atara Biotherapeutics (NASDAQ:ATRA) investors has not been profitable (Simply Wall St.)
Feb-08-23 05:15PM	Atara Biotherapeutics (ATRA) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -7.69%
04:01PM	Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress (Business Wire)
06:00AM	Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO (tabelecleucel) (Business Wire)
Feb-06-23 08:00AM	Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on Wednesday, February 8, 2023 (Business Wire)
Feb-03-23 04:01PM	Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.31%
Jan-13-23 04:01PM	Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-04-23 04:01PM	Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-24-22 10:07AM	3 Under-the-Radar Biotech Stocks to Buy in 2022 (Motley Fool)
Dec-20-22 04:33PM	Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty (Business Wire)
Dec-19-22 08:00AM	Atara Biotherapeutics Announces Changes to Its Board of Directors (Business Wire)
07:00AM	Atara Biotherapeutics Ebvallo (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD (Business Wire)
Dec-15-22 04:01PM	Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -10.82%
Dec-12-22 10:00AM	Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 64th American Society of Hematology (ASH) Annual Meeting (Business Wire)
Dec-02-22 04:01PM	Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +8.18%
Nov-23-22 08:00AM	Atara Biotherapeutics to Participate at the Evercore ISI 5th Annual HealthCONx Conference (Business Wire)
Nov-22-22 05:03AM	Newsflash: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Analysts Have Been Trimming Their Revenue Forecasts (Simply Wall St.)
Nov-10-22 05:52AM	Atara Biotherapeutics Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS In Line (Simply Wall St.) +23.97%
Nov-09-22 04:01PM	Atara Biotherapeutics to Participate at the Stifel Healthcare Conference (Business Wire) -20.82%
Nov-08-22 05:15PM	Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress (Business Wire)
Nov-04-22 04:01PM	Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-01-22 04:05PM	Atara Biotherapeutics to Announce Third Quarter 2022 Financial Results on Tuesday, November 8, 2022 (Business Wire)
Oct-26-22 02:01AM	Atara Biotherapeutics Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022 (Business Wire)
Oct-14-22 07:08AM	CHMP Recommends Approval of Atara Biotherapeutics Ebvallo (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (Business Wire) -6.52%
Oct-13-22 12:51PM	BioMarin (BMRN) Hemophilia Gene Therapy BLA Gets FDA Acceptance (Zacks)
Oct-10-22 04:01PM	Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-07-22 10:01AM	Allogene (ALLO) Begins Phase II Study on Allogeneic CAR T Therapy (Zacks) -8.61%
Oct-06-22 01:36PM	Acadia (ACAD) Rises More Than 14% in 3 Months: Here's Why (Zacks)
Sep-30-22 08:59AM	Horizon (HZNP) Completes Enrollment in Phase IV TED Study (Zacks)
Sep-29-22 11:09AM	Sanofi's (SNY) Dupixent Gets FDA Nod for Prurigo Nodularis (Zacks) -5.47%
07:30AM	Atara Biotherapeutics to Receive Additional Near-Term Milestone Under Updated Tab-cel Commercialization Pact (Benzinga)
Sep-28-22 04:01PM	Atara Biotherapeutics to Receive Additional Near-Term Milestone Payment Under Updated Tabelecleucel (Tab-cel®) Commercialization Agreement with Pierre Fabre (Business Wire) +15.32%
01:47PM	Merck's (MRK) Keytruda Gets Four New Approvals in Japan (Zacks)
Sep-27-22 10:13AM	Emergent (EBS) Acquires Worldwide Rights to Smallpox Antiviral (Zacks)
Sep-21-22 06:32PM	Alnylam's (ALNY) Rare Disease Drug Amvuttra Gets EC Nod (Zacks) -5.53%
Sep-13-22 03:45PM	Horizon's (HZNP) Phase II Sjogren's Syndrome Study Meets Goal (Zacks) -6.92%

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Touchon Pascal	President and CEO	Mar 04 '24	Sale	0.72	24,844	17,888	1,910,652	Mar 06 06:19 PM
Nguyen AnhCo	EVP, Chief Sci. & Tech Officer	Mar 04 '24	Sale	0.72	10,746	7,737	941,397	Mar 06 06:18 PM
Murugan Amar	EVP, Chief Legal Officer	Mar 04 '24	Sale	0.72	10,044	7,232	727,521	Mar 06 06:18 PM
Henrich Jill	EVP, Global Head RA & Quality	Mar 04 '24	Sale	0.72	3,879	2,793	555,001	Mar 06 06:16 PM
Touchon Pascal	President and CEO	Nov 16 '23	Sale	0.39	20,409	7,939	655,496	Nov 20 05:31 PM
Joshi Manher	EVP, Chief Medical Officer	Nov 16 '23	Sale	0.39	12,287	4,780	171,284	Nov 20 05:30 PM
Hyllengren Eric J	SVP, CFO	Nov 16 '23	Sale	0.39	11,958	4,652	205,998	Nov 20 05:29 PM
Nguyen AnhCo	EVP, Chief Sci. & Tech Officer	Nov 16 '23	Sale	0.39	8,856	3,445	277,143	Nov 20 05:31 PM
Murugan Amar	EVP, Chief Legal Officer	Nov 16 '23	Sale	0.39	8,307	3,231	257,084	Nov 20 05:30 PM
Henrich Jill	EVP, Global Head RA & Quality	Nov 16 '23	Sale	0.39	3,267	1,271	104,424	Nov 20 05:29 PM
Gallagher Carol Giltner	Director	Nov 14 '23	Buy	0.31	90,980	28,186	459,418	Nov 15 05:07 PM
Gallagher Carol Giltner	Director	Nov 13 '23	Buy	0.22	179,020	40,029	368,438	Nov 15 05:07 PM
DOBMEIER ERIC	Director	Nov 10 '23	Buy	0.23	446,825	101,340	563,325	Nov 14 06:27 PM
HEIDEN WILLIAM K	Director	Nov 10 '23	Buy	0.25	100,000	25,330	209,000	Nov 14 06:29 PM
Touchon Pascal	President and CEO	Aug 16 '23	Sale	1.65	30,766	50,835	675,905	Aug 18 06:25 PM
Nguyen AnhCo	EVP, Chief Sci. & Tech Officer	Aug 16 '23	Sale	1.65	15,126	24,997	285,999	Aug 18 06:25 PM
Murugan Amar	EVP, Chief Legal Officer	Aug 16 '23	Sale	1.65	8,672	14,330	265,391	Aug 18 06:25 PM
Hyllengren Eric J	SVP, CFO	Aug 16 '23	Sale	1.65	8,186	13,527	217,956	Aug 18 06:25 PM
Joshi Manher	EVP, Chief Medical Officer	Aug 16 '23	Sale	1.65	6,975	11,526	183,571	Aug 18 06:25 PM
Henrich Jill	EVP, Global Head RA & Quality	Aug 16 '23	Sale	1.65	3,346	5,531	107,691	Aug 18 06:25 PM
Touchon Pascal	President and CEO	Jun 27 '23	Sale	1.66	14,291	23,723	706,671	Jun 29 04:15 PM
Touchon Pascal	President and CEO	May 16 '23	Sale	2.04	29,766	60,633	720,962	May 18 08:17 PM
Banard Charlene A.	EVP, Chief Technical Officer	May 16 '23	Sale	2.04	19,040	38,784	276,010	May 18 08:17 PM
Murugan Amar	EVP, Chief Legal Officer	May 16 '23	Sale	2.04	8,389	17,089	270,945	May 18 08:17 PM
Hyllengren Eric J	SVP, CFO	May 16 '23	Sale	2.04	7,918	16,131	226,142	May 18 08:17 PM

Open in Screener

GOSS

Gossamer Bio Inc

Apr 18 • 04:00PM ET

0.8060

Dollar change -0.0140
Percentage change -1.71	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF VHT SCHA IWC SCHB

Index	-	P/E	-	EPS (ttm)	-1.38	Insider Own	16.27%	Shs Outstand	225.41M	Perf Week	-16.69%
Market Cap	181.82M	Forward P/E	-	EPS next Y	-0.70	Insider Trans	0.51%	Shs Float	188.87M	Perf Month	-42.01%
Income	-179.82M	PEG	-	EPS next Q	-0.19	Inst Own	79.44%	Short Float	5.70%	Perf Quarter	-7.32%
Sales	0.00M	P/S	-	EPS this Y	35.82%	Inst Trans	11.74%	Short Ratio	8.33	Perf Half Y	26.17%
Book/sh	0.28	P/B	2.89	EPS next Y	6.95%	ROA	-61.54%	Short Interest	10.76M	Perf Year	-17.73%
Cash/sh	1.31	P/C	0.61	EPS next 5Y	5.20%	ROE	-480.50%	52W Range	0.45 - 1.88	Perf YTD	-11.67%
Dividend Est.	-	P/FCF	-	EPS past 5Y	11.99%	ROI	-69.08%	52W High	-57.13%	Beta	1.81
Dividend TTM	-	Quick Ratio	5.94	Sales past 5Y	0.00%	Gross Margin	-	52W Low	78.12%	ATR (14)	0.09
Dividend Ex-Date	-	Current Ratio	5.94	EPS Y/Y TTM	49.48%	Oper. Margin	0.00%	RSI (14)	26.39	Volatility	8.90% 8.09%
Employees	135	Debt/Eq	3.38	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.80	Target Price	5.72
Option/Short	Yes / Yes	LT Debt/Eq	3.15	EPS Q/Q	63.89%	Payout	-	Rel Volume	0.59	Prev Close	0.82
Sales Surprise	-	EPS Surprise	-0.82%	Sales Q/Q	-	Earnings	Mar 05 BMO	Avg Volume	1.29M	Price	0.81
SMA20	-26.66%	SMA50	-31.60%	SMA200	-19.14%	Trades		Volume	768,484	Change	-1.71%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-05-24	Resumed	Wedbush	Outperform	$4
Jul-27-23	Downgrade	UBS	Buy → Neutral	$8 → $1.25
Mar-07-23	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-01-23	Initiated	Guggenheim	Neutral
Dec-07-22	Downgrade	SMBC Nikko	Outperform → Neutral	$3
Dec-07-22	Downgrade	JP Morgan	Neutral → Underweight
Dec-07-22	Downgrade	Barclays	Overweight → Equal Weight	$18 → $2
Oct-20-22	Initiated	Goldman	Buy	$22
Sep-21-22	Initiated	JP Morgan	Neutral	$17
Sep-19-22	Initiated	Wedbush	Outperform	$24
Apr-18-22	Initiated	Raymond James	Outperform	$19
Apr-06-22	Initiated	UBS	Buy	$19
Jan-10-22	Upgrade	SMBC Nikko	Neutral → Outperform	$24
Nov-09-21	Resumed	Cantor Fitzgerald	Overweight	$20
Sep-21-21	Resumed	Piper Sandler	Overweight	$26
Jun-29-20	Initiated	H.C. Wainwright	Buy	$31
Apr-22-20	Initiated	Piper Sandler	Overweight	$30
Feb-27-20	Initiated	Barclays	Overweight	$21
Dec-03-19	Resumed	BofA/Merrill	Buy
Oct-30-19	Initiated	Berenberg	Buy	$31

Show Previous Ratings

Mar-13-24 07:07AM	13 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
Mar-12-24 07:31AM	Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors (Business Wire)
Mar-07-24 09:55AM	Should You Buy Gossamer Bio (GOSS) After Golden Cross? (Zacks) -7.95%
Mar-05-24 10:52PM	GOSS Stock Earnings: Gossamer Bio Meets EPS for Q4 2023 (InvestorPlace)
07:55AM	Gossamer Bio Posts Narrower Loss In Q4 - Quick Facts (RTT News)
07:40AM	Loading…
07:40AM	Gossamer Bio: Q4 Earnings Snapshot (Associated Press Finance)
07:31AM	Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update (Business Wire)
Feb-27-24 03:30AM	12 Best Medical Stocks to Buy Under $10 (Insider Monkey)
Jan-31-24 02:23PM	7 Micro-Cap Stocks That Could Majorly Surprise Investors (InvestorPlace)
Jan-22-24 10:53AM	5 Small-Cap Stocks with High Potential (Insider Monkey)
Jan-08-24 04:01PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +8.24%
Dec-13-23 04:01PM	Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023 (Business Wire)
Dec-05-23 04:01PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.31%
07:01AM	Gossamer Bio Appoints Bob Smith as Chief Commercial Officer (Business Wire)
Nov-29-23 07:01AM	Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors (Business Wire)
08:11AM	Loading…
Nov-09-23 08:11AM	Gossamer Bio Inc (GOSS) Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com) -7.56%
07:41AM	Gossamer Bio: Q3 Earnings Snapshot (Associated Press Finance)
07:31AM	Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Oct-23-23 10:08AM	12 Best Penny Stocks to Buy Under $1 (Insider Monkey) -6.46%
Oct-03-23 04:08PM	Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs (Business Wire) -5.57%
Sep-07-23 07:44AM	Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023 (Business Wire)
Aug-28-23 08:20AM	TENX: Second Quarter Results (Zacks)
Aug-08-23 04:41PM	Gossamer Bio: Q2 Earnings Snapshot (Associated Press Finance) -5.43%
04:01PM	Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Jul-24-23 04:16PM	Gossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE Results (Business Wire)
Jul-20-23 07:56AM	Gossamer Bio Announces $212 Million Private Placement Financing (Business Wire) -31.87%
Jun-23-23 06:24AM	TENX: Notice of Allowance Increases Confidence (Zacks Small Cap Research)
May-18-23 07:05AM	Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference (Business Wire) +7.58%
May-13-23 08:15AM	In the wake of Gossamer Bio, Inc.'s (NASDAQ:GOSS) latest US$15m market cap drop, institutional owners may be forced to take severe actions (Simply Wall St.)
May-09-23 04:13PM	Gossamer Bio: Q1 Earnings Snapshot (AP Finance)
04:01PM	Loading…
04:01PM	Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Apr-04-23 12:38PM	After Pausing Recruitment, Gossamer Bio Terminates All Studies With CNS Lymphoma Candidate (Benzinga) -9.38%
Mar-17-23 07:46AM	Gossamer Bio: Q4 Earnings Snapshot (AP Finance) -8.47%
07:31AM	Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update (Business Wire)
Mar-07-23 03:37PM	Analyst Downgrades Gossamer Bio As Merck's Sotatercept Might Overshadow Seralutinib's Success (Benzinga)
Mar-03-23 11:40AM	15 Most Shorted Stocks Right Now on Wall Street (Insider Monkey)
Feb-01-23 04:25PM	7 Top Short-Squeeze Candidates to Watch in February (InvestorPlace) +7.20%
Jan-04-23 12:00PM	Gossamer Bio (GOSS) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +5.39%
09:35AM	Gossamer Bio (GOSS) Loses -13.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Dec-26-22 09:41AM	Bullish insiders at Gossamer Bio, Inc. (NASDAQ:GOSS) loaded up on US$1.2m of stock earlier this year (Simply Wall St.)
Dec-06-22 01:19PM	Analyst Turns Bullish On Aerovate As Competitor Data Reinforce Lead Program Thesis (Benzinga) -74.60%
10:00AM	Gossamer Bio Shares Plummet As Hypertension Trial Fall Short Of Expectation (Benzinga)
08:19AM	Gossamer Bio's stock falls 64% on findings for Phase 2 study for hypertension drug (MarketWatch)
07:15AM	Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH (Business Wire)
Nov-17-22 02:37PM	Analyst Expects 'Somewhat Smaller Effect Size' From Gossamer Bio's Upcoming PAH Trial (Benzinga)
Nov-08-22 12:00PM	What Makes Gossamer Bio (GOSS) a New Buy Stock (Zacks)
Nov-03-22 04:01PM	Gossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Oct-24-22 08:30AM	Goldman Sachs Says These 2 Buy-Rated Stocks Have at Least 60% Upside Potential (TipRanks)
Aug-29-22 08:11AM	With 62% ownership of the shares, Gossamer Bio, Inc. (NASDAQ:GOSS) is heavily dominated by institutional owners (Simply Wall St.)
Aug-09-22 08:01AM	Gossamer Bio Announces Second Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Jul-21-22 06:21PM	2 Strong Buy Stocks That In-The-Know Bigwigs Are Pouring Money Into (TipRanks)
Jul-20-22 11:33AM	Squeezable AMC, GameStop stocks break out to multi-month highs (MarketWatch)
Jul-19-22 12:00PM	Here's Why Gossamer Bio (GOSS) is a Great Momentum Stock to Buy (Zacks) +6.29%
09:46AM	The Co-Founder of Gossamer Bio, Inc. (NASDAQ:GOSS), Faheem Hasnain, Just Bought 3.8% More Shares (Simply Wall St.)
Jul-18-22 09:55AM	Wall Street Analysts See a 52% Upside in Gossamer Bio (GOSS): Can the Stock Really Move This High? (Zacks)
Jul-13-22 07:15AM	Gossamer Bio Announces $120 Million Private Placement Financing (Business Wire) +31.90%
Jun-09-22 08:30AM	Gossamer Bio Announces Publication of Key Preclinical Data in the European Respiratory Journal Highlighting Seralutinibs Potential for the Treatment of PAH (Business Wire)
May-26-22 09:55AM	Wall Street Analysts Believe Gossamer Bio (GOSS) Could Rally 113%: Here's is How to Trade (Zacks)
May-23-22 09:55AM	Gossamer Bio (GOSS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
May-10-22 04:01PM	Gossamer Bio Announces First Quarter 2022 Financial Results and Provides Business Update (Business Wire) +11.70%
May-06-22 12:20PM	Is Gossamer Bio (NASDAQ:GOSS) Weighed On By Its Debt Load? (Simply Wall St.) -7.01%
Apr-25-22 07:29AM	Gossamer Bio Announces GB004 Topline Results from Phase 2 SHIFT-UC Study in Ulcerative Colitis and Provides Corporate Update (Business Wire)
Mar-03-22 04:01PM	Gossamer Bio Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Business Update (Business Wire)
Feb-28-22 07:01AM	Gossamer Bio to Announce Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 3, 2022 (Business Wire)
Jan-02-22 08:47AM	What Kind Of Investors Own Most Of Gossamer Bio, Inc. (NASDAQ:GOSS)? (Simply Wall St.)
Nov-08-21 04:01PM	Gossamer Bio Announces Third Quarter 2021 Financial Results and Provides Corporate Update (Business Wire)
Nov-02-21 04:01PM	Gossamer Bio to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021 (Business Wire)
Oct-11-21 08:36AM	Gossamer Bio Announces Addition of Two CNS-Penetrant BTK Inhibitors to its Product Candidate Pipeline: GB5121 & GB7208 (Business Wire) +6.52%
Oct-07-21 04:01PM	Gossamer Bio to Host Webcast Announcing its Next Clinical Product Candidates on October 11, 2021 (Business Wire)
Oct-03-21 10:45AM	Is Gossamer Bio (NASDAQ:GOSS) Weighed On By Its Debt Load? (Simply Wall St.)
Sep-21-21 08:31AM	Gossamer Bio Announces Appointment of Bryan Giraudo as Chief Operating Officer, in addition to Chief Financial Officer Role (Business Wire) +10.63%
Aug-09-21 04:01PM	Gossamer Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update (Business Wire)
Aug-02-21 04:01PM	Gossamer Bio to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 9, 2021 (Business Wire)
Jul-21-21 05:16AM	Hedge Funds Are Selling Gossamer Bio, Inc. (GOSS) (Insider Monkey)
Jul-17-21 05:47AM	Gossamer Bio, Inc. (NASDAQ:GOSS) Insiders Increased Their Holdings (Simply Wall St.)
Jul-07-21 07:01AM	Gossamer Bio Announces GB004 Clinical Trial Data Presentations at 2021 Virtual Congress of the European Crohns and Colitis Organisation (Business Wire)
Jun-21-21 04:01PM	Gossamer Bio Announces Promotion of Richard Aranda, M.D., to Chief Medical Officer (Business Wire)
Jun-14-21 04:01PM	Gossamer Bio Announces Appointment of Sandra Milligan, M.D., J.D., to its Board of Directors (Business Wire)
May-06-21 07:31AM	Gossamer Bio Announces First Quarter 2021 Financial Results and Provides Corporate Update (Business Wire)
Apr-20-21 07:50AM	Gossamer Bio Announces Executive Management Transition and Promotion of Laura Carter, Ph.D., to Chief Scientific Officer (Business Wire)
Apr-16-21 07:55AM	Gossamer Bio Announces Promotion of Caryn Peterson to Executive Vice President, Regulatory Affairs (Business Wire)
Feb-25-21 07:31AM	Gossamer Bio Announces Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Update (Business Wire) -5.59%
Feb-19-21 08:01AM	Gossamer Bio to Announce Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on February 25, 2021 (Business Wire)
Feb-04-21 07:05AM	Gossamer Bio to Host Webcast Focused on its Inflammatory Bowel Disease Program, GB004, on February 18, 2021 (Business Wire)
Jan-18-21 03:05AM	Have Insiders Been Buying Gossamer Bio, Inc. (NASDAQ:GOSS) Shares This Year? (Simply Wall St.)
Dec-19-20 03:54PM	Is GOSS A Good Stock To Buy Now According To Hedge Funds? (Insider Monkey)
Dec-11-20 05:00PM	Aerpio Announces Statistically Significant Topline Results from Razuprotafib Glaucoma Phase 2 Trial (GlobeNewswire)
Dec-07-20 07:03AM	Gossamer Bio to Host Webcast Focused on GB002 and Pulmonary Arterial Hypertension (PAH) on December 15, 2020 (Business Wire)
Nov-16-20 07:01AM	Gossamer Bio Announces Appointment of Faheem Hasnain as Chief Executive Officer (Business Wire)
Nov-10-20 04:01PM	Gossamer Bio Announces Third Quarter 2020 Financial Results and Provides Corporate Update (Business Wire)
02:30PM	Gossamer Bio, Inc. to Host Earnings Call (ACCESSWIRE)
08:00AM	Aerpio Reports Third Quarter 2020 Financial Results and Provides Business Update (GlobeNewswire)
Nov-06-20 07:07AM	Gossamer Bio to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 10, 2020 (Business Wire)
07:03AM	Gossamer Bio Announces GB1275 Data Presentations at 2020 Society for Immunotherapy of Cancer Annual Meeting (Business Wire)
Oct-13-20 03:02PM	Hedge Funds Are Piling Into Gossamer Bio, Inc. (GOSS) (Insider Monkey) -25.75%
07:04AM	Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis (Business Wire)
Oct-12-20 08:07AM	Gossamer Bio Announces Presentation of GB004 Phase 1b Clinical Data at United European Gastroenterology Virtual Week 2020 and Additional Program Updates (Business Wire)
Oct-09-20 08:01AM	Gossamer Bio Announces GB004 Data Presentations at United European Gastroenterology Virtual Week 2020 (Business Wire)
Sep-30-20 08:38AM	Are Options Traders Betting on a Big Move in Gossamer Bio (GOSS) Stock? (Zacks)
Sep-10-20 07:07AM	Gossamer Bio Announces Participation in Upcoming Investor Conferences (Business Wire)

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hasnain Faheem	President & CEO	Mar 27 '24	Sale	1.16	23,172	26,773	120,293	Mar 28 06:01 PM
Giraudo Bryan	COO/CFO	Mar 27 '24	Sale	1.16	6,430	7,431	92,737	Mar 28 06:05 PM
Christian Waage	EVP, Tech Ops and Admin	Mar 27 '24	Sale	1.16	6,430	7,430	585,934	Mar 28 06:16 PM
Peterson Caryn	EVP, Regulatory Affairs	Mar 18 '24	Sale	1.33	4,018	5,343	49,833	Mar 19 06:50 PM
Aranda Richard	Chief Medical Officer	Mar 18 '24	Sale	1.33	4,018	5,342	198,799	Mar 19 06:50 PM
Milligan Sandra	Director	Nov 15 '23	Buy	0.79	32,000	25,213	32,000	Nov 17 04:01 PM
Giraudo Bryan	COO/CFO	Nov 13 '23	Buy	0.56	200,000	112,880	380,010	Nov 14 06:24 PM
Aranda Richard	Chief Medical Officer	Jun 22 '23	Sale	1.29	1,814	2,340	197,574	Jun 26 04:01 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

ATRA

Atara Biotherapeutics Inc

GOSS

Gossamer Bio Inc

Upgrade your FINVIZ experience